Cadrenal Therapeutics (CVKD) Non Operating Income (2022 - 2026)
Cadrenal Therapeutics (CVKD) posted Non Operating Income of $52129.0 for Q3 2024, down 29.21% sequentially from $73636.0 in Q2 2024, and down 50.89% YoY from $106145.0 in Q4 2023.
Cadrenal Therapeutics (CVKD) Non Operating Income (2022 - 2026) Analysis & Trends
Cadrenal Therapeutics has reported Non Operating Income for 3 years, with the latest figure at $52129.0 in Q3 2024.
- Quarterly Non Operating Income fell 50.89% year-over-year to $52129.0 in Q3 2024, while the trailing twelve-month figure through Sep 2024 was $337863.0 (up 107.07% YoY) and the FY2023 annual result came in at -$724243.0, up 81.95% from the prior year.
- Non Operating Income eased to $52129.0 in Q3 2024 per CVKD's latest filing, from $73636.0 in the prior quarter.
- Over five years, Non Operating Income peaked at $119771.0 in Q4 2023 and troughed at -$3.9 million in Q4 2022.
- A 3-year average of -$451272.5 and a median of $37652.5 in 2023 frame the typical range for Non Operating Income.
- The sharpest annual moves came in 2023 and 2024: Non Operating Income surged 299.06% in 2023, then sank 50.89% in 2024.
- Over 3 years, Non Operating Income stood at -$3.9 million in 2022, then surged by 103.04% to $119771.0 in 2023, then plunged by 56.48% to $52129.0 in 2024.
- According to Business Quant data, Non Operating Income over the past three periods registered $52129.0, $73636.0, and $92327.0 for Q3 2024, Q2 2024, and Q1 2024 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 234.30 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -53.64 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -51.63 Mn |
| 10 | Cadrenal Therapeutics | 4.59 Mn | 2.19 Mn | - | 17,835.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 17,835.00 |
| Jun 30, 2025 | 67,004.00 |
| Sep 30, 2024 | 52,129.00 |
| Jun 30, 2024 | 73,636.00 |
| Mar 31, 2024 | 92,327.00 |
| Dec 31, 2023 | 119,771.00 |
| Sep 30, 2023 | 106,145.00 |
| Jun 30, 2023 | 23,176.00 |
| Mar 31, 2023 | -973,335.00 |
| Dec 31, 2022 | -3.93 Mn |
| Sep 30, 2022 | -53,323.00 |
| Jun 30, 2022 | -19,794.00 |